title: [Gastric carcinoma: an evolutionary scenario.]
abstract: Despite the progressive decline of its incidence and mortality over the past decades, gastric cancer remains the forth most common cause of cancer-related death in Europe. While historically gastric adenocarcinoma has been classified according to the Lauren classification in intestinal and diffuse subtype, the knowledge of the complex molecular mechanisms underlying its carcinogenesis has led to new molecular classifications which can represent the starting point for the development of a personalized approach also in this disease. From a clinical point of view, while the addition of trastuzumab in the therapeutic armamentarium paved the way for the introduction of targeted therapy in the first-line treatment, only recently the confirmation of the role of second-line therapy along with the approval of ramucirumab as a standard of care in this setting led to a new concept of "continuum of care" in gastric cancer. Furthermore, also the pivotal role of nutritional counseling and support both in early- and advanced-stage disease has been recently confirmed in many retrospective and prospective series.
authors.affiliation: Dipartimento di Oncologia ed Ematologia, Azienda Ospedaliero-Universitaria Policlinico di Modena, Università di Modena e Reggio Emilia.
authors.forename: Fabio
authors.initials: F
authors.lastname: Gelsomino
authors.affiliation: Dipartimento di Oncologia ed Ematologia, Azienda Ospedaliero-Universitaria Policlinico di Modena, Università di Modena e Reggio Emilia.
authors.forename: Andrea
authors.initials: A
authors.lastname: Spallanzani
authors.affiliation: Dipartimento di Medicina Interna e Sperimentale "F. Magrassi", Divisione di Oncologia Medica, Università della Campania "Luigi Vanvitelli".
authors.forename: Ferdinando
authors.initials: F
authors.lastname: De Vita
authors.affiliation: Oncologia Medica Gastroenterologica, Fondazione IRCCS Istituto Nazionale Tumori, Milano.
authors.forename: Maria
authors.initials: M
authors.lastname: Di Bartolomeo
authors.affiliation: Unità di Terapia Nutrizionale, Fondazione IRCCS Istituto Nazionale Tumori, Milano.
authors.forename: Cecilia
authors.initials: C
authors.lastname: Gavazzi
authors.affiliation: UO Oncologia Medica, Humanitas Cancer Center, Humanitas Research Hospital - IRCCS, Rozzano (Milano).
authors.forename: Lorenza
authors.initials: L
authors.lastname: Rimassa
authors.affiliation: Dipartimento di Oncologia ed Ematologia, Azienda Ospedaliero-Universitaria Policlinico di Modena, Università di Modena e Reggio Emilia.
authors.forename: Stefano
authors.initials: S
authors.lastname: Cascinu
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000628:therapy*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage; D006801:Humans; D058990:Molecular Targeted Therapy; D009367:Neoplasm Staging; D057285:Precision Medicine / Q000379:methods; D013274:Stomach Neoplasms / Q000473:pathology / Q000628:therapy*; D000068878:Trastuzumab / Q000008:administration & dosage; D000096662:Ramucirumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab; D000096662:Ramucirumab